Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;10(2):642-648.
doi: 10.1002/cam4.3648. Epub 2020 Dec 25.

A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia

Pierre Peterlin  1   2 , Joelle Gaschet  2 , Thierry Guillaume  1   2 , Alice Garnier  1 , Marion Eveillard  2   3 , Amandine Le Bourgeois  1 , Michel Cherel  2   4 , Camille Debord  3 , Yannick Le Bris  2   3 , Olivier Theisen  3 , Catherine Godon  3 , Béatrice Mahé  1 , Viviane Dubruille  1 , Soraya Wuilleme  3 , Cyrille Touzeau  1 , Thomas Gastinne  1 , Nicolas Blin  1 , Anne Lok  1 , Benoît Tessoulin  1 , Steven Le Gouill  1   2 , Philippe Moreau  1   2 , Marie-C Béné  2   3 , Patrice Chevallier  1   2
Affiliations

A new cytokine-based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia

Pierre Peterlin et al. Cancer Med. 2021 Jan.

Abstract

The aim of this study was to assess the potential impact of the kinetics of serum levels of seven cytokines during induction in acute myeloid leukemia (AML) patients. Indeed, the role of cytokines, in the pathophysiology and response to therapy of AML patients, remains under investigation. Here, we report on the impact of peripheral levels of two cytokines, the Fms-like tyrosine kinase 3 ligand (FL) and interleukin-6 (IL-6), evaluated during first-line intensive induction. A new risk stratification can be proposed, which supersedes the ELN 2017 classification to predict survivals in AML patients by examining the kinetic profile of these cytokines during the induction phase. It segregates three groups of, respectively, high-risk, characterized by a stagnation of low FL levels, intermediate risk, with dynamic increasing FL levels and high IL-6 at day 22, and favorable risk with increasing FL levels but low IL-6 at day 22.

Keywords: FLT3 ligand; IL-6; acute myeloid leukemia; prognostic biomarker.

PubMed Disclaimer

Conflict of interest statement

All authors declare no potential financial conflicts.

Figures

FIGURE 1
FIGURE 1
Leukemia‐free survival (LFS), and overall survival (OS). Survivals according to ELN2017 classification (ELN) and to the new cytokine model stratification (FL IL‐6)
See this image and copyright information in PMC

References

    1. Binder S, Luciano M, Horejs‐Hoeck J. The cytokine network in acute myeloid leukemia (AML): a focus on pro‐ and anti‐inflammatory mediators. Cytokine Growth Factor Rev. 2018;43:8‐15. - PubMed
    1. Carey A, Edwards DK 5th, Eide CA, et al. Identification of interleukin‐1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18:3204‐3218. - PMC - PubMed
    1. Sun YX, Kong HL, Liu CF, et al. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Hum Immunol. 2014;75:113‐118. - PubMed
    1. Sanchez‐Correa B, Bergua JM, Campos C, et al. Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL‐6 and directly correlated with IL‐10 levels. Cytokine. 2013;61:885‐891. - PubMed
    1. Tsapogas P, Mooney CJ, Brown G, et al. The cytokine Flt3‐ligand in normal and malignant hematopoiesis [Internet]. Int J Mol Sci. 2017;18:pii:E1115. - PMC - PubMed

Publication types